Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
0.7261
-0.0015 (-0.21%)
At close: Nov 13, 2026, 4:00 PM EST
0.7300
+0.0039 (0.54%)
After-hours: Nov 13, 2026, 7:42 PM EST
Cardiff Oncology Revenue
Cardiff Oncology had revenue of $171.00K in the quarter ending September 30, 2026, with 42.50% growth. This brings the company's total for the last twelve months to $559.00K, up 11.58% year-over-year. In the year 2025, Cardiff Oncology had annual revenue of $593.00K, down -13.18%. That makes Cardiff Oncology the 44,449th largest company in the world by revenue and 6,311th in the United States.
Revenue (ttm)
$559.00K
Revenue Growth
+11.58%
P/S Ratio
101.05
Revenue / Employee
$18,032
Employees
31
Market Cap
56.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 593.00K | -90.00K | -13.18% |
| Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
| Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
| Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
| Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
| Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
| Dec 31, 2019 | 244.63K | -133.69K | -35.34% |
| Dec 31, 2018 | 378.33K | -127.08K | -25.14% |
| Dec 31, 2017 | 505.40K | 124.33K | 32.63% |
| Dec 31, 2016 | 381.07K | 68.26K | 21.82% |
| Dec 31, 2015 | 312.81K | 32.63K | 11.65% |
| Dec 31, 2014 | 280.18K | 20.93K | 8.07% |
| Dec 31, 2013 | 259.25K | -191.16K | -42.44% |
| Dec 31, 2012 | 450.40K | 192.71K | 74.78% |
| Dec 31, 2011 | 257.70K | -273.63K | -51.50% |
| Dec 31, 2010 | 531.33K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Xilio Therapeutics | 55.01M |
| Tonix Pharmaceuticals Holding | 43.05M |
| Spero Therapeutics | 41.56M |
| Clene | 238.00K |
CRDF News
- 3 days ago - Cardiff Oncology reports Q3 EPS (12c), consensus (13c) - TheFly
- 3 days ago - Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 3 days ago - Cardiff Oncology Quarterly report: Q3 2026 - Filings
- 3 days ago - Cardiff Oncology Earnings release: Q3 2026 - Filings
- 5 days ago - Cardiff Oncology small cell lung cancer treatment gets orphan status - TheFly
- 12 days ago - Cardiff Oncology to Participate in the UBS Global Biopharma Conference - GlobeNewsWire
- 18 days ago - Cardiff Oncology names Leila Alland interim chief medical officer - TheFly
- 18 days ago - Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer - GlobeNewsWire